"BIO believes that the PTO's proposed rule changes will stifle biotech innovation," BIO President & CEO Jim Greenwood stated. "It can take decades to develop a patented biotechnology invention, in part because these inventions must go through a rigorous regulatory approval process. Strong patent protections are needed to allow biotech companies to attract the investment needed to survive the long process of bringing a product to market. The changes in the PTO's proposed rule will discourage investors from investing money in biotech innovations."
The PTO claims however that the rule changes are needed to address concerns about patent quality and to reduce the large number of backlogged patent cases.
Read more at BIO.
.jpg)
Comment Preview